Ras-proximate-1 (RAP1): a prognosis and therapeutic target in the metastatic spread of breast cancer
- PMID: 40214810
- DOI: 10.1007/s10585-025-10342-5
Ras-proximate-1 (RAP1): a prognosis and therapeutic target in the metastatic spread of breast cancer
Abstract
Breast cancer (BC), a highly heterogeneous disease, has demonstrated a gradual increase in both incidence and mortality rates. At present, it has become one of the most common malignant tumors and the main cause of cancer death worldwide. While early screening is recognized as an effective preventive and therapeutic measure for BC, the disease continues to exhibit a high rate of metastasis. Metastatic BC is still the main cause of poor prognosis and death of patients, necessitating urgent investigation and resolution. Among the various metastatic sites of BC, bone metastases warrant particular attention due to their prevalence. In numerous studies on BC bone metastasis mechanisms, cancer markers have been shown to significantly influence the pattern and extent of BC metastasis and dissemination. In the tumor microenvironment, Ras-proximate-1 (RAP1), a GTPase protein, is not only upregulated in various malignant tumors and bone-related diseases, including BC, but also regulates migration, invasion, distant metastasis, and other signaling pathways in numerous malignant tumor cells, including BC as well. Despite these findings, there remains a paucity of advanced research and discussion on the relationship between RAP1 and BC bone metastasis. Furthermore, no clinically approved RAP1-related inhibitors for BC bone metastasis are currently available. Nevertheless, RAP1 and its associated signaling molecules represent potential molecular targets for the prevention and treatment of BC bone metastasis, warranting further investigation. Therefore, this article provides a comprehensive review of RAP1's pathogenic role in BC bone metastasis, emphasizes RAP1 and its associated signaling pathways, and summarizes current research on natural compounds and extracts that modulate BC bone metastasis via RAP1 or RAP1-related signaling pathways. This review aims to offer novel perspectives for developing RAP1 as a potential molecular target in the prevention and treatment of BC bone metastasis, as well as for the development of related therapeutic agents.
Keywords: Bone metastasis; Breast cancer; Inflammation; Microenvironment; Ras-proximate-1; Treatment.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
The molecular signature of breast cancer metastasis to bone.Anticancer Drugs. 2016 Oct;27(9):824-31. doi: 10.1097/CAD.0000000000000401. Anticancer Drugs. 2016. PMID: 27384592
-
Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2.Cancer Sci. 2014 Jan;105(1):18-25. doi: 10.1111/cas.12309. Epub 2013 Dec 4. Cancer Sci. 2014. PMID: 24164962 Free PMC article.
-
Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis.Breast Cancer Res. 2024 Dec 18;26(1):186. doi: 10.1186/s13058-024-01934-2. Breast Cancer Res. 2024. PMID: 39696397 Free PMC article.
-
Genetics of breast cancer bone metastasis: a sequential multistep pattern.Clin Exp Metastasis. 2014 Jun;31(5):595-612. doi: 10.1007/s10585-014-9642-9. Epub 2014 Feb 4. Clin Exp Metastasis. 2014. PMID: 24493024 Review.
-
Therapeutics targeting the metastatic breast cancer bone microenvironment.Pharmacol Ther. 2022 Nov;239:108280. doi: 10.1016/j.pharmthera.2022.108280. Epub 2022 Sep 16. Pharmacol Ther. 2022. PMID: 36116682 Review.
References
-
- Zeng L, Li W, Chen CS (2020) Breast cancer animal models and applications. Zoological Res 41(5):477–494. https://doi.org/10.24272/j.issn.2095-8137.2020.095 - DOI
-
- Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P (2022) SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast cancer Research: BCR 24(1):99. https://doi.org/10.1186/s13058-022-01596-y - DOI - PubMed - PMC
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 - DOI
-
- Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncology: Official J Am Soc Clin Oncol 28(20):3271–3277. https://doi.org/10.1200/JCO.2009.25.9820 - DOI
-
- Xu Y, Li X, Zhang S, Tang M, Yu R, Liao X, Li Z, Li M, Chen S, Qian W, Song L, Ke Z, Li J (2024) CircMMP2(6,7) cooperates with β-Catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis. Cancer Res 84(2):328–343. https://doi.org/10.1158/0008-5472.CAN-23-1899 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical